Global Pharmaceutical CDMO Market Projected to Reach US$ 217203 Mn by 2029| Thermo Fisher Scientific, Catalent, Lonza

LOS ANGELES, United States: The global Pharmaceutical CDMO market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Pharmaceutical CDMO market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Pharmaceutical CDMO market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Pharmaceutical CDMO market. We have also focused on SWOT, PESTLE, and Porter's Five Forces analyses of the global Pharmaceutical CDMO market.

Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) estimated at US$ 139345 million in the year 2023, is projected to reach a revised size of US$ 217203 million by 2029, growing at a CAGR of 7.68% during the forecast period 2023-2029.

The US & Canada market for Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) is estimated to increase from $ 37855 million in 2023 to reach $ 50454 million by 2029, at a CAGR of 4.9% during the forecast period of 2023 through 2029.

The China market for Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) is estimated to increase from $ 17129 million in 2023 to reach $ 51175 million by 2029, at a CAGR of 20.01% during the forecast period of 2023 through 2029.

The Europe market for Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) is estimated to increase from $ 28502 million in 2023 to reach $ 36462 million by 2029, at a CAGR of 4.19% during the forecast period of 2024 through 2029.

Get PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/sample-form/form/5551972/Global-Pharmaceutical-CDMO-Pharmaceutical-Contract-Development-and-Manufacturing-Organization-Market-Insights-Forecast-to-2029

Key Players Mentioned in the Global Pharmaceutical CDMO Market Research Report:

Catalent

Thermo Fisher Scientific

Lonza

Siegfried

Recipharm

Boehringer Ingelheim

WuXi AppTech

WuXi Biologics

Fareva

Samsung Biologics

Aenova

Delpharm

Strides Pharma

Piramal

Famar

Curia

Jubilant

Vetter

AGC Pharma Chemicals

Asymchem

Porton

Eurofins

Ascendia Pharmaceuticals

Ardena

CPL

UPM Pharmaceuticals

FUJIFILM Diosynth Biotechnologies

Groupe Parima

TBD Pharmatech

Avid Bioservices

NextPharma

Alcami

Societal CDMO

MedPharm

Euroapi

BioVectra

Pfizer CentreOne

Fermion

Lundbeck

Our market analysts are experts in deeply segmenting the global Pharmaceutical CDMO market and thoroughly evaluating the growth potential of each and every segment studied in the report. Right at the beginning of the research study, the segments are compared on the basis of consumption and growth rate for a review period of nine years. The segmentation study included in the report offers a brilliant analysis of the global Pharmaceutical CDMO market, taking into consideration the market potential of different segments studied. It assists market participants to focus on high-growth areas of the global Pharmaceutical CDMO market and plan powerful business tactics to secure a position of strength in the industry.

This report focuses on the Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization)revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

Global Pharmaceutical CDMO Market by Type:

API CDMO

FDF CDMO

Packaging CDMO

Clinical CDMO

Global Pharmaceutical CDMO Market by Application:

Pharmaceutical Company

Biotechnology Company

Others

Pharmaceutical CDMO market research study is incomplete without regional analysis, and we are well aware of it. That is why, the report includes a comprehensive and all-inclusive study that solely concentrates on the geographical growth of the global Pharmaceutical CDMO market. The study also includes accurate estimations about market growth at the global, regional, and country levels. It empowers you to understand why some regional markets are flourishing while others are seeing a decline in growth. It also allows you to focus on geographies that hold the potential to create lucrative prospects in the near future.

This report researches the key producers of Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization), also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization), and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This Pharmaceutical CDMO Market Research Report Contains Answers to your following Questions

(A) Which Manufacturing Technology is Used for Pharmaceutical CDMO? What Developments Are Going On in That Technology? Which Trends Are Causing These Developments?

(B) Who Are the Global Key Players in This Pharmaceutical CDMO Market? What's Their Company Profile, Their Product Information, and Contact Information?

(C) What Was Global Market Status of Pharmaceutical CDMO Market? What Was Capacity, Production Value, Cost and PROFIT of Pharmaceutical CDMO Market?

(D) What Is Current Market Status of Pharmaceutical CDMO Industry? What's Market Competition in This Industry, Both Company, and Country Wise? What's Market Analysis of Pharmaceutical CDMO Market by Taking Applications and Types in Consideration?

(E) What Are Projections of Global Pharmaceutical CDMO Industry Considering Capacity, Production and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply and Consumption? What about Import and Export?

(F) What Is Pharmaceutical CDMO Market Chain Analysis by Upstream Raw Materials and Downstream Industry?

(G) What Is Economic Impact On Pharmaceutical CDMO Industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends?

(H) What Are Market Dynamics of Pharmaceutical CDMO Market? What Are Challenges and Opportunities?

(I) What Should Be Entry Strategies, Countermeasures to Economic Impact, Marketing Channels for Pharmaceutical CDMO Industry?

Request for customization in Report: https://www.qyresearch.com/customize-request/form/5551972/Global-Pharmaceutical-CDMO-Pharmaceutical-Contract-Development-and-Manufacturing-Organization-Market-Insights-Forecast-to-2029

Table of Content

1 Report Overview 1

1.1 Study Scope 1

1.2 Market Analysis by Type 1

1.2.1 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size Growth Rate by Type: 2018 VS 2022 VS 2029 1

1.2.2 Clinical CDMO 4

1.2.3 API CDMO 4

1.2.4 FDF CDMO 4

1.2.5 Packaging CDMO 5

1.3 Market by Application 6

1.3.1 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Application: 2018 VS 2022 VS 2029 6

1.3.2 Pharmaceutical Company 9

1.3.3 Biotechnology Company 9

1.4 Assumptions and Limitations 9

1.5 Study Objectives 10

1.6 Years Considered 11

2 Global Growth Trends 12

2.1 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Perspective (2018-2029) 12

2.2 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Growth Trends by Region 14

2.2.1 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Region: 2018 VS 2022 VS 2029 15

2.2.2 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Historic Market Size by Region (2018-2023) 16

2.2.3 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Forecasted Market Size by Region (2024-2029) 17

2.3 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Dynamics 18

2.3.1 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Industry Trends 18

2.3.2 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Drivers 20

2.3.3 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Challenges 21

2.3.4 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Restraints 22

3 Competition Landscape by Key Players 23

3.1 Global Revenue Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) by Players 23

3.1.1 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue by Players (2018-2023) 23

3.1.2 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue Market Share by Players (2018-2023) 25

3.2 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) by Company Type (Tier 1, Tier 2, and Tier 3) 28

3.3 Global Key Players of Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization), Ranking by Revenue, 2021 VS 2022 29

3.4 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Concentration Ratio 32

3.4.1 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Concentration Ratio (CR5 and HHI) 32

3.4.2 Global Top 10 and Top 5 Companies by Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Revenue in 2022 33

3.5 Global Key Players of Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Head office and Production Site 34

3.6 Founded Date of Global Key Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Players 36

3.7 Mergers & Acquisitions, Expansion Plans 38

4 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Breakdown Data by Type 41

4.1 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Historic Market Size by Type (2018-2023) 41

4.2 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Forecasted Market Size by Type (2024-2029) 42

5 Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Breakdown Data by Application 44

5.1 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Historic Market Size by Application (2018-2023) 44

5.2 Global Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Forecasted Market Size by Application (2024-2029) 45

6 North America 46

6.1 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size (2018-2029) 46

6.2 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type 47

6.2.1 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type (2018-2023) 47

6.2.2 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type (2024-2029) 47

6.2.3 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Type (2018-2029) 48

6.3 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application 49

6.3.1 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2018-2023) 49

6.3.2 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2024-2029) 49

6.3.3 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Application (2018-2029) 50

6.4 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Country 51

6.4.1 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Country: 2018 VS 2022 VS 2029 51

6.4.2 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Country (2018-2023) 51

6.4.3 North America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Country (2024-2029) 52

6.4.4 United States 53

6.4.5 Canada 53

7 Europe 54

7.1 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size (2018-2029) 54

7.2 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type 55

7.2.1 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type (2018-2023) 55

7.2.2 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type (2024-2029) 55

7.2.3 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Type (2018-2029) 56

7.3 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application 57

7.3.1 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2018-2023) 57

7.3.2 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2024-2029) 57

7.3.3 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Application (2018-2029) 58

7.4 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Country 59

7.4.1 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Country: 2018 VS 2022 VS 2029 59

7.4.2 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Country (2018-2023) 59

7.4.3 Europe Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Country (2024-2029) 60

7.4.4 Germany 61

7.4.5 France 62

7.4.6 U.K. 62

7.4.7 Italy 63

7.4.8 Russia 63

8 China 64

8.1 China Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size (2018-2029) 64

8.2 China Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type 65

8.2.1 China Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type (2018-2023) 65

8.2.2 China Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type (2024-2029) 65

8.2.3 China Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Type (2018-2029) 66

8.3 China Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application 67

8.3.1 China Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2018-2023) 67

8.3.2 China Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2024-2029) 67

8.3.3 China Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Application (2018-2029) 68

9 Asia (excluding China) 69

9.1 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size (2018-2029) 69

9.2 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type 70

9.2.1 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type (2018-2023) 70

9.2.2 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type (2024-2029) 70

9.2.3 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Type (2018-2029) 71

9.3 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application 71

9.3.1 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2018-2023) 71

9.3.2 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2024-2029) 72

9.3.3 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Application (2018-2029) 73

9.4 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Region 74

9.4.1 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Region: 2018 VS 2022 VS 2029 74

9.4.2 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Region (2018-2023) 74

9.4.3 Asia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Region (2024-2029) 75

9.4.4 Japan 76

9.4.5 South Korea 77

9.4.6 Southeast Asia 77

9.4.7 India 78

9.4.8 Australia 78

10 Middle East, Africa, and Latin America 79

10.1 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size (2018-2029) 79

10.2 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type 80

10.2.1 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type (2018-2023) 80

10.2.2 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Type (2024-2029) 80

10.2.3 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Type (2018-2029) 81

10.3 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application 82

10.3.1 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2018-2023) 82

10.3.2 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Application (2024-2029) 82

10.3.3 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Share by Application (2018-2029) 83

10.4 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Country 84

10.4.1 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Country: 2018 VS 2022 VS 2029 84

10.4.2 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Country (2018-2023) 84

10.4.3 Middle East, Africa, and Latin America Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Market Size by Country (2024-2029) 85

10.4.4 Brazil 86

10.4.5 Mexico 87

10.4.6 Middle East 87

10.4.7 Africa 88

11 Key Players Profiles 89

11.1 Catalent 89

11.1.1 Catalent Company Details 89

11.1.2 Catalent Business Overview 89

11.1.3 Catalent Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 91

11.1.4 Catalent Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 93

11.1.5 Catalent Recent Development 93

11.2 Thermo Fisher Scientific 94

11.2.1 Thermo Fisher Scientific Company Details 94

11.2.2 Thermo Fisher Scientific Business Overview 94

11.2.3 Thermo Fisher Scientific Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 95

11.2.4 Thermo Fisher Scientific Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 97

11.2.5 Thermo Fisher Scientific Recent Development 97

11.3 Lonza 97

11.3.1 Lonza Company Details 97

11.3.2 Lonza Business Overview 98

11.3.3 Lonza Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 100

11.3.4 Lonza Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 101

11.3.5 Lonza Recent Development 101

11.4 Siegfried 102

11.4.1 Siegfried Company Details 102

11.4.2 Siegfried Business Overview 102

11.4.3 Siegfried Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 103

11.4.4 Siegfried Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 105

11.4.5 Siegfried Recent Development 105

11.5 Recipharm 105

11.5.1 Recipharm Company Details 105

11.5.2 Recipharm Business Overview 106

11.5.3 Recipharm Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 107

11.5.4 Recipharm Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 108

11.5.5 Recipharm Recent Development 109

11.6 Boehringer Ingelheim 109

11.6.1 Boehringer Ingelheim Company Details 109

11.6.2 Boehringer Ingelheim Business Overview 110

11.6.3 Boehringer Ingelheim Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 110

11.6.4 Boehringer Ingelheim Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 111

11.6.5 Boehringer Ingelheim Recent Development 111

11.7 WuXi AppTech 112

11.7.1 WuXi AppTech Company Details 112

11.7.2 WuXi AppTech Business Overview 113

11.7.3 WuXi AppTech Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 113

11.7.4 WuXi AppTech Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 114

11.7.5 WuXi AppTech Recent Development 114

11.8 WuXi Biologics 115

11.8.1 WuXi Biologics Company Details 115

11.8.2 WuXi Biologics Business Overview 115

11.8.3 WuXi Biologics Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 116

11.8.4 WuXi Biologics Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 117

11.8.5 WuXi Biologics Recent Development 117

11.9 Fareva 118

11.9.1 Fareva Company Details 118

11.9.2 Fareva Business Overview 118

11.9.3 Fareva Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 119

11.9.4 Fareva Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 119

11.9.5 Fareva Recent Development 120

11.10 Samsung Biologics 120

11.10.1 Samsung Biologics Company Details 120

11.10.2 Samsung Biologics Business Overview 121

11.10.3 Samsung Biologics Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 121

11.10.4 Samsung Biologics Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 122

11.10.5 Samsung Biologics Recent Development 123

11.11 Aenova 123

11.11.1 Aenova Company Details 123

11.11.2 Aenova Business Overview 124

11.11.3 Aenova Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 124

11.11.4 Aenova Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 126

11.11.5 Aenova Recent Development 127

11.12 Delpharm 127

11.12.1 Delpharm Company Details 127

11.12.2 Delpharm Business Overview 128

11.12.3 Delpharm Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 128

11.12.4 Delpharm Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 130

11.12.5 Delpharm Recent Development 130

11.13 Strides Pharma 131

11.13.1 Strides Pharma Company Details 131

11.13.2 Strides Pharma Business Overview 131

11.13.3 Strides Pharma Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 132

11.13.4 Strides Pharma Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 133

11.13.5 Strides Pharma Recent Development 133

11.14 Piramal 133

11.14.1 Piramal Company Details 133

11.14.2 Piramal Business Overview 134

11.14.3 Piramal Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 135

11.14.4 Piramal Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 135

11.14.5 Piramal Recent Development 136

11.15 Famar 136

11.15.1 Famar Company Details 136

11.15.2 Famar Business Overview 137

11.15.3 Famar Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 137

11.15.4 Famar Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 138

11.15.5 Famar Recent Development 139

11.16 Curia 139

11.16.1 Curia Company Details 139

11.16.2 Curia Business Overview 140

11.16.3 Curia Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 140

11.16.4 Curia Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 141

11.16.5 Curia Recent Development 141

11.17 Jubilant 142

11.17.1 Jubilant Company Details 142

11.17.2 Jubilant Business Overview 142

11.17.3 Jubilant Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 143

11.17.4 Jubilant Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 144

11.17.5 Jubilant Recent Development 144

11.18 Vetter Pharma 145

11.18.1 Vetter Pharma Company Details 145

11.18.2 Vetter Pharma Business Overview 145

11.18.3 Vetter Pharma Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 146

11.18.4 Vetter Pharma Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 146

11.18.5 Vetter Pharma Recent Development 146

11.19 AGC Pharma Chemicals 147

11.19.1 AGC Pharma Chemicals Company Details 147

11.19.2 AGC Pharma Chemicals Business Overview 148

11.19.3 AGC Pharma Chemicals Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 148

11.19.4 AGC Pharma Chemicals Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 150

11.19.5 AGC Pharma Chemicals Recent Development 150

11.20 Asymchem 151

11.20.1 Asymchem Company Details 151

11.20.2 Asymchem Business Overview 151

11.20.3 Asymchem Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 152

11.20.4 Asymchem Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 153

11.20.5 Asymchem Recent Development 153

11.21 Porton 154

11.21.1 Porton Company Details 154

11.21.2 Porton Business Overview 154

11.21.3 Porton Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 155

11.21.4 Porton Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 156

11.21.5 Porton Recent Development 156

11.22 Eurofins 156

11.22.1 Eurofins Company Details 156

11.22.2 Eurofins Business Overview 157

11.22.3 Eurofins Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 158

11.22.4 Eurofins Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 159

11.22.5 Eurofins Recent Development 159

11.23 Ascendia Pharmaceuticals 160

11.23.1 Ascendia Pharmaceuticals Company Details 160

11.23.2 Ascendia Pharmaceuticals Business Overview 160

11.23.3 Ascendia Pharmaceuticals Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 161

11.23.4 Ascendia Pharmaceuticals Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 161

11.23.5 Ascendia Pharmaceuticals Recent Development 162

11.24 Ardena 162

11.24.1 Ardena Company Details 162

11.24.2 Ardena Business Overview 163

11.24.3 Ardena Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 163

11.24.4 Ardena Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 164

11.24.5 Ardena Recent Development 164

11.25 CPL 165

11.25.1 CPL Company Details 165

11.25.2 CPL Business Overview 165

11.25.3 CPL Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 166

11.25.4 CPL Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 166

11.25.5 CPL Recent Development 166

11.26 UPM Pharmaceuticals 167

11.26.1 UPM Pharmaceuticals Company Details 167

11.26.2 UPM Pharmaceuticals Business Overview 167

11.26.3 UPM Pharmaceuticals Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 168

11.26.4 UPM Pharmaceuticals Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 168

11.26.5 UPM Pharmaceuticals Recent Development 169

11.27 FUJIFILM Diosynth Biotechnologies 169

11.27.1 FUJIFILM Diosynth Biotechnologies Company Details 169

11.27.2 FUJIFILM Diosynth Biotechnologies Business Overview 170

11.27.3 FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 170

11.27.4 FUJIFILM Diosynth Biotechnologies Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 171

11.27.5 FUJIFILM Diosynth Biotechnologies Recent Development 171

11.28 Groupe Parima 172

11.28.1 Groupe Parima Company Details 172

11.28.2 Groupe Parima Business Overview 172

11.28.3 Groupe Parima Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 173

11.28.4 Groupe Parima Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 174

11.29 TBD Pharmatech 174

11.29.1 TBD Pharmatech Company Details 174

11.29.2 TBD Pharmatech Business Overview 175

11.29.3 TBD Pharmatech Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 175

11.29.4 TBD Pharmatech Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 176

11.30 Avid Bioservices 176

11.30.1 Avid Bioservices Company Details 176

11.30.2 Avid Bioservices Business Overview 177

11.30.3 Avid Bioservices Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 177

11.30.4 Avid Bioservices Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 178

11.31 NextPharma 178

11.31.1 NextPharma Company Details 178

11.31.2 NextPharma Business Overview 179

11.31.3 NextPharma Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 180

11.31.4 NextPharma Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 181

11.31.5 NextPharma Recent Development 182

11.32 Alcami 183

11.32.1 Alcami Company Details 183

11.32.2 Alcami Business Overview 183

11.32.3 Alcami Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 184

11.32.4 Alcami Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 186

11.32.5 Alcami Recent Development 186

11.33 Societal CDMO 186

11.33.1 Societal CDMO Company Details 186

11.33.2 Societal CDMO Business Overview 187

11.33.3 Societal CDMO Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 188

11.33.4 Societal CDMO Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 189

11.33.5 Societal CDMO Recent Development 189

11.34 MedPharm 190

11.34.1 MedPharm Company Details 190

11.34.2 MedPharm Business Overview 191

11.34.3 MedPharm Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 192

11.34.4 MedPharm Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 192

11.35 Euroapi 193

11.35.1 Euroapi Company Details 193

11.35.2 Euroapi Business Overview 193

11.35.3 Euroapi Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 194

11.35.4 Euroapi Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 195

11.35.5 Euroapi Recent Development 195

11.36 BioVectra 196

11.36.1 BioVectra Company Details 196

11.36.2 BioVectra Business Overview 197

11.36.3 BioVectra Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 198

11.36.4 BioVectra Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 199

11.37 Pfizer CentreOne 199

11.37.1 Pfizer CentreOne Company Details 199

11.37.2 Pfizer CentreOne Business Overview 200

11.37.3 Pfizer CentreOne Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 200

11.37.4 Pfizer CentreOne Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 201

11.37.5 Pfizer CentreOne Recent Development 201

11.38 Fermion 202

11.38.1 Fermion Company Details 202

11.38.2 Fermion Business Overview 203

11.38.3 Fermion Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 205

11.38.4 Fermion Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 206

11.38.5 Fermion Recent Development 206

11.39 Lundbeck 207

11.39.1 Lundbeck Company Details 207

11.39.2 Lundbeck Business Overview 208

11.39.3 Lundbeck Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Introduction 209

11.39.4 Lundbeck Revenue in Pharmaceutical CDMO (Pharmaceutical Contract Development and Manufacturing Organization) Business (2018-2023) 211

11.39.5 Lundbeck Recent Development 211

12 Analyst's Viewpoints/Conclusions 213

13 Appendix 216

13.1 Research Methodology 216

13.1.1 Methodology/Research Approach 216

13.1.2 Data Source 219

13.2 Author Details 222

13.3 Disclaimer 224

Contact US

QY RESEARCH, INC.
17890 CASTLETON STREET
SUITE 369, CITY OF INDUSTRY
CA - 91748, UNITED STATES OF AMERICA
+1 626 539 9760 / +91 8669986909
ankit@qyresearch.com / enquiry@qyresearch.com

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), expert's resources (included energy automotive chemical medical ICT consumer goods etc.

This release was published on openPR.